Study Evaluating Immune Response and Species-Based Treatment in Leishmania Infection

What this Trial Is About

This research focuses on patients with active Leishmania infection, aiming to diagnose and classify the infection while studying the natural history and host factors contributing to resistant or relapsing disease. The study also investigates the host immune response before and after therapy to better understand disease diagnosis, progression, and treatment response. Patients receive optimal clinical care while contributing valuable samples for laboratory research on leishmanial infections. Participants receive species-based treatment appropriate to their infection. Standard evaluations include biopsies to obtain parasite and host tissue. Following treatment, patients have follow-up visits at 3 months, 6 months remote check-in via photo, telephone, or telehealth, and 12 months to monitor disease progression and treatment response. Additional visits may be scheduled as needed based on clinical status. Samples such as blood, lesion swabs, mucosal swabs, microbiopsies, and skin biopsies are collected for research purposes throughout the study. During the study, participants undergo physical examinations and provide various biological samples for research evaluation. The study tracks clinical and immunologic responses over time, with long-term follow-up beyond one year if clinically necessary. Research measurements include immune workups, genomic data collection, and clinical documentation of disease course to assess treatment safety and effectiveness. Participants can also be evaluated remotely if their physicians can submit required specimens. The total participation duration typically extends to one year post-treatment, with possible annual follow-ups thereafter.

Diagnosis and Treatment of Leishmania Infections